Sign Out
The general contraindications for administering Numeta as an activated 2 chamber bag for intravenous infusion are as follows: Hypersensitivity to egg, soy or peanut proteins, or to any of the active substances, excipients listed in Description, or components of the container.
Congenital abnormality of the amino acid metabolism.
Pathologically elevated plasma concentrations of sodium, potassium, magnesium, calcium and/or phosphorus.
Severe hyperglycaemia.
The addition of lipids (administering Numeta as an activated 3 chamber bag for intravenous emulsion) is contraindicated in the following additional clinical situations: Severe hyperlipidaemia, or severe disorders of lipid metabolism characterized by hypertriglyceridemia.
Numeta G13%E: Concomitant treatment with ceftriaxone, even if separate infusion lines are used. See Precautions, Interactions and Incompatibilities under Cautions for Usage.
Numeta G16%E: As for other calcium-containing infusion solutions, concomitant treatment with ceftriaxone in newborn infants (≤28 days of age), even if separate infusion lines are used (risk of fatal ceftriaxone calcium salt precipitation in the neonate's bloodstream). See Precautions, Interactions and Incompatibilities under Cautions for Usage.
